This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (544)

Published on in Vol 5, No 2 (2016): Apr-Jun

Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study

Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study

Early Monitoring of Response (MORE) to Golimumab Therapy Based on Fecal Calprotectin and Trough Serum Levels in Patients With Ulcerative Colitis: A Multicenter Prospective Study

Authors of this article:

Attyla Drabik1 Author Orcid Image ;   Andreas Sturm2 Author Orcid Image ;   Margit Blömacher3 Author Orcid Image ;   Ulf Helwig4 Author Orcid Image
Article Authors Cited by (4) Tweetations Metrics

Journals

  1. Flamant M, Paul S, Roblin X. Golimumab for the treatment of ulcerative colitis. Expert Opinion on Biological Therapy 2017;17(7):879 View
  2. Walczak M, Lykowska-Szuber L, Plucinska M, Stawczyk-Eder K, Zakerska-Banaszak O, Eder P, Krela-Kazmierczak I, Michalak M, Zywicki M, Karlowski W, Szalata M, Dobrowolska A, Slomski R, Skrzypczak-Zielinska M. Is Polymorphism in the Apoptosis and Inflammatory Pathway Genes Associated With a Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients?. Frontiers in Pharmacology 2020;11 View
  3. Lopetuso L, Gerardi V, Papa V, Scaldaferri F, Rapaccini G, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents?. International Journal of Molecular Sciences 2017;18(9):1973 View
  4. Helwig U, Krause T, Maaser C, Büning J, Drabik A, Blömacher M, Plachta-Danielzik S, Teich N, Krummenerl A, Sturm A, Schwab M, Schreiber S. Early MOnitoring of REsponse (MORE) to Golimumab Therapy: Results of a Multicentre, Prospective Observational Trial. Digestive Diseases 2023;41(2):239 View